Lauren Harrison
New York Medical College
72 Papers
307 Citations
Lauren Harrison is an academic researcher from New York Medical College. The author has contributed to research in topics: Medicine & Transplantation. The author has an hindex of 17, co-authored 54 publications.
Chat about Author
Papers
Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.
S. Goldman,Lynette M. Smith,James R. Anderson,Sherrie L. Perkins,Lauren Harrison,Mark B. Geyer,Thomas G. Gross,Howard J. Weinstein,Sharon Bergeron,Bruce Shiramizu,Warren G. Sanger,Matthew J. Barth,J. Zhi,Mitchell S. Cairo +13 more
TL;DR: Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report
151
Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients.
Prakash Satwani,Zhezhen Jin,Deirdre Duffy,Erin Morris,Monica Bhatia,James Garvin,Diane George,M.B. Bradley,Lauren Harrison,Kristen Petrillo,Joseph E. Schwartz,Sandra Foley,R. Hawks,Lee Ann Baxter-Lowe,Mitchell S. Cairo +14 more
TL;DR: Reduced-toxicity conditioning allo-HSCT in pediatric recipients is associated with low TRM; however, chemotherapy-naive UCBT recipients have a significantly higher incidence of PGF.
75
Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.
Mitchell S. Cairo,Anne Auperin,Sherrie L. Perkins,Ross Pinkerton,Lauren Harrison,Stanton Goldman,Catherine Patte +6 more
TL;DR: New therapeutic strategies are required to significantly reduce refractory disease and disease relapse in patients with newly diagnosed mature B‐NHL and, more importantly, there is a critical need to develop novel retrieval approaches in patientsWith chemotherapy‐resistant disease.
62
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
E. Roman,E. Cooney,Lauren Harrison,O. Militano,K. Wolownik,R. Hawks,Sandi Foley,Prakash Satwani,Elif Unal,Monica Bhatia,Brigid Bradley,Gustavo Del Toro,Diane George,James Garvin,Carmella van de Ven,Mitchell S. Cairo +15 more
TL;DR: The administration of gemtuzumab ozogamicin post reduced-intensity allogeneic SCT in children with average risk AML is feasible and well tolerated with minimal toxicity.
54
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
Mark B. Geyer,Judith S. Jacobson,Jason L. Freedman,Diane George,Virginia Moore,Carmella van de Ven,Prakash Satwani,Monica Bhatia,James Garvin,M.B. Bradley,Lauren Harrison,Erin Morris,Phyllis Della-Latta,Joseph Schwartz,Lee Ann Baxter-Lowe,Mitchell S. Cairo +15 more
TL;DR: The use of adoptive cellular immunotherapy to accelerate immune reconstitution and prevent and treat opportunistic infections and malignant relapse following UCBT warrants further investigation.
50